UY37698A - Proteínas de unión a antígenos trem2 y usos de estas - Google Patents

Proteínas de unión a antígenos trem2 y usos de estas

Info

Publication number
UY37698A
UY37698A UY0001037698A UY37698A UY37698A UY 37698 A UY37698 A UY 37698A UY 0001037698 A UY0001037698 A UY 0001037698A UY 37698 A UY37698 A UY 37698A UY 37698 A UY37698 A UY 37698A
Authority
UY
Uruguay
Prior art keywords
trem2
antigen binding
binding proteins
proteins
antigens
Prior art date
Application number
UY0001037698A
Other languages
English (en)
Spanish (es)
Inventor
Irwin Chen
Ian Nevin Foltz
Susie Miki Harris
Shilpa Sambashivan
Dora Toledo Warshaviak
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY37698A publication Critical patent/UY37698A/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • C07K2317/53Hinge
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55Fab or Fab'
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74Inducing cell proliferation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75Agonist effect on antigen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
UY0001037698A 2017-04-21 2018-04-24 Proteínas de unión a antígenos trem2 y usos de estas UY37698A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762488691P 2017-04-21 2017-04-21
US201762530753P 2017-07-10 2017-07-10
US201762580400P 2017-11-01 2017-11-01

Publications (1)

Publication Number Publication Date
UY37698A true UY37698A (es) 2018-10-31

Family

ID=63856168

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001037698A UY37698A (es) 2017-04-21 2018-04-24 Proteínas de unión a antígenos trem2 y usos de estas

Country Status (21)

Country Link
US (2) US11186636B2 (OSRAM)
EP (2) EP3612218B1 (OSRAM)
JP (2) JP7252134B2 (OSRAM)
KR (2) KR102772851B1 (OSRAM)
CN (1) CN110709100A (OSRAM)
AU (2) AU2018254600B2 (OSRAM)
BR (1) BR112019021991A2 (OSRAM)
CA (1) CA3060409A1 (OSRAM)
CL (2) CL2019003000A1 (OSRAM)
CO (1) CO2019012998A2 (OSRAM)
CR (2) CR20190525A (OSRAM)
ES (1) ES3035028T3 (OSRAM)
JO (1) JOP20190248A1 (OSRAM)
MA (1) MA52273A (OSRAM)
MX (2) MX2019012364A (OSRAM)
PE (2) PE20250782A1 (OSRAM)
PH (1) PH12019502356A1 (OSRAM)
SG (1) SG11201909646TA (OSRAM)
TW (2) TW202423975A (OSRAM)
UY (1) UY37698A (OSRAM)
WO (1) WO2018195506A1 (OSRAM)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
WO2017062672A2 (en) * 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
JOP20190248A1 (ar) * 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
CA3061755A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CA3127808A1 (en) * 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CA3146777A1 (en) * 2019-08-02 2021-02-11 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and pharmaceutical use thereof
EP3986937A1 (en) * 2019-12-05 2022-04-27 Alector LLC Methods of use of anti-trem2 antibodies
WO2021146256A1 (en) * 2020-01-13 2021-07-22 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
JP2023512450A (ja) * 2020-01-13 2023-03-27 デナリ セラピューティクス インコーポレイテッド 抗trem2抗体及びその使用方法
JP2023510994A (ja) * 2020-01-20 2023-03-16 中外製薬株式会社 リガンド結合融合タンパク質
JP7745557B2 (ja) 2020-02-24 2025-09-29 アレクトル エルエルシー 抗trem2抗体の使用方法
MX2022012182A (es) * 2020-04-03 2022-12-08 Alector Llc Metodos de uso de anticuerpos anti-trem2.
PE20230609A1 (es) * 2020-05-04 2023-04-13 Amgen Inc Compuestos heterociclicos como agonistas del receptor de activacion expresado en las celulas mieloides 2 y metodos de uso
CR20230069A (es) * 2020-08-05 2023-08-16 Vigil Neuroscience Inc Tratamiento de enfermedades relacionadas con la disfunción del receptor del factor 1 estimulante de colonias con agonistas de trem2
MX2023006598A (es) * 2020-12-03 2023-08-22 Amgen Inc Biomarcadores agonistas del trem2 y métodos para usarlos.
US20230082623A1 (en) * 2020-12-04 2023-03-16 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
WO2023047100A1 (en) * 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
CA3239455A1 (en) * 2021-11-22 2023-05-25 Vigil Neuroscience, Inc. Anti-trem2 antibody and uses thereof
WO2023114499A1 (en) 2021-12-17 2023-06-22 Denali Therapeutics Inc. Polypeptide engineering, libraries, and engineered cd98 heavy chain and transferrin receptor binding polypeptides
CN118765204A (zh) 2022-02-23 2024-10-11 艾利妥 抗trem2抗体的使用方法
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2024253420A1 (ko) * 2023-06-09 2024-12-12 재단법인대구경북과학기술원 인간 trem2 단백질에 특이적으로 결합하는 인간 항체 및 이의 용도
WO2025015713A1 (zh) * 2023-07-19 2025-01-23 成都优洛生物科技有限公司 抗trem2人源化抗体、其抗原结合片段及其应用
US20250101101A1 (en) 2023-09-01 2025-03-27 iTeos Belgium SA Anti-trem2 antibodies and methods of use
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025166058A1 (en) * 2024-01-31 2025-08-07 Alector Llc Multi-specific proteins that bind to trem2 and transferrin receptor and uses therefor
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
CN118420764A (zh) * 2024-04-02 2024-08-02 上海宏成药业有限公司 抗trem2抗体及其用途
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (239)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30985A (en) 1860-12-18 Thomas l
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US4965195A (en) 1987-10-26 1990-10-23 Immunex Corp. Interleukin-7
US4968607A (en) 1987-11-25 1990-11-06 Immunex Corporation Interleukin-1 receptors
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU643427B2 (en) 1988-10-31 1993-11-18 Immunex Corporation Interleukin-4 receptors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
ATE356869T1 (de) 1990-01-12 2007-04-15 Amgen Fremont Inc Bildung von xenogenen antikörpern
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
AU651596B2 (en) 1990-06-05 1994-07-28 Immunex Corporation Type II interleukin-1 receptors
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
CA2089661C (en) 1990-08-29 2007-04-03 Nils Lonberg Transgenic non-human animals capable of producing heterologous antibodies
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
CA2111348A1 (en) 1991-06-14 1992-12-23 John S. Logan Production of human hemoglobin in transgenic pigs
JPH06508880A (ja) 1991-07-08 1994-10-06 ユニバーシティ オブ マサチューセッツ アット アムハースト サーモトロピック液晶セグメント化ブロックコポリマー
EP1136556B1 (en) 1991-11-25 2005-06-08 Enzon, Inc. Method of producing multivalent antigen-binding proteins
SG48760A1 (en) 1992-07-24 2003-03-18 Abgenix Inc Generation of xenogenetic antibodies
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
ATE390933T1 (de) 1995-04-27 2008-04-15 Amgen Fremont Inc Aus immunisierten xenomäusen stammende menschliche antikörper gegen il-8
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
CA2284131A1 (en) 1997-03-07 1998-09-11 Human Genome Sciences, Inc. 70 human secreted proteins
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
AU4834999A (en) 1998-06-26 2000-01-17 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
US6660843B1 (en) 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
SI2857516T1 (sl) 2000-04-11 2017-09-29 Genentech, Inc. Multivalentna protitelesa in njihove uporabe
US7858094B2 (en) 2000-12-08 2010-12-28 Geneprint Corporation TREM-1 splice variant for use in modifying immune responses
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20030113316A1 (en) 2001-07-25 2003-06-19 Kaisheva Elizabet A. Stable lyophilized pharmaceutical formulation of IgG antibodies
EP2316485A1 (en) 2001-10-12 2011-05-04 Schering Corporation Use of bispecific antibodies to regulate immune responses
EP1530590A2 (en) 2002-03-22 2005-05-18 Bioxell S.p.a. Triggering receptors expressed on myeloid cells (trem)-4 and -5 and uses thereof
CA2489145A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited Insulin-sensitizing agent
US7388079B2 (en) 2002-11-27 2008-06-17 The Regents Of The University Of California Delivery of pharmaceutical agents via the human insulin receptor
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
CN102139106B (zh) 2004-05-27 2014-10-08 克鲁塞尔荷兰公司 能中和狂犬病病毒的结合分子及其应用
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
KR20060135280A (ko) 2005-06-24 2006-12-29 전남대학교산학협력단 선천성 면역에 관여하는 트렘-2의 클로닝
EP1959969A2 (en) 2005-07-01 2008-08-27 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
KR101516823B1 (ko) 2006-03-17 2015-05-07 바이오겐 아이덱 엠에이 인코포레이티드 안정화된 폴리펩티드 조성물
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
AU2007257692B2 (en) 2006-06-12 2013-11-14 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
CA2551163A1 (en) 2006-07-17 2008-01-17 Boehringer Ingelheim International Gmbh Methods for treating inflammatory, autoimmune or bone resorption diseases
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
EP2121750A2 (en) 2007-01-16 2009-11-25 Wyeth Inflammation treatment, detection and monitoring via trem-1
EP3202786A3 (en) 2007-03-12 2017-10-11 ESBATech, an Alcon Biomedical Research Unit LLC Sequence based engineering and optimization of single chain antibodies
US8793074B2 (en) 2007-06-21 2014-07-29 Saint Louis University Sequence covariance networks, methods and uses therefor
CA2689941C (en) 2007-06-25 2019-10-29 Esbatech Ag Methods of modifying antibodies, and modified antibodies with improved functional properties
GR1007327B (el) 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
AU2008298904B2 (en) 2007-09-14 2014-10-16 Amgen Inc. Homogeneous antibody populations
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
WO2009089004A1 (en) 2008-01-07 2009-07-16 Amgen Inc. Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ga733-2 발현 억제제로서의 trem-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
WO2010045479A1 (en) 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
EP2424976B1 (en) 2009-04-28 2013-07-31 Life & Brain GmbH Method for obtaining human microglial precursor cells from pluripotent stem cells
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
AU2010270979B2 (en) 2009-06-22 2015-04-23 Medimmune, Llc Engineered Fc regions for site-specific conjugation
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
CN102038698A (zh) 2009-10-14 2011-05-04 山东绿叶天然药物研究开发有限公司 莫诺苷的新用途
JO3244B1 (ar) * 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
WO2011056997A1 (en) * 2009-11-04 2011-05-12 Fabrus Llc Methods for affinity maturation-based antibody optimization
CN102127168A (zh) 2010-01-19 2011-07-20 中国人民解放军第二军医大学 一种髓样细胞表达激发受体-1的重组融合蛋白及其应用
KR20110086460A (ko) 2010-01-22 2011-07-28 한국교원대학교산학협력단 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
DK2555789T3 (da) 2010-04-08 2020-07-20 Inst Nat Sante Rech Med Hæmmende peptider afledt af trem-lignende transcript 1 (tlt-1) og anvendelser deraf
WO2011137362A1 (en) 2010-04-30 2011-11-03 Rother Russell P Antibodies having reduced immunogenicity in a human
WO2012016333A1 (en) 2010-08-06 2012-02-09 University Health Network Biomarkers for malaria
US20130130354A1 (en) 2010-09-28 2013-05-23 CTI Salud S.A. Novel genes and uses thereof, expression profile of colon, gastric and pancreatic cancer
US20120195900A1 (en) 2010-12-22 2012-08-02 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US20120201746A1 (en) 2010-12-22 2012-08-09 Abbott Laboratories Half immunoglobulin binding proteins and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
CA2829628A1 (en) 2011-03-11 2012-09-20 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
KR20120112973A (ko) 2011-04-04 2012-10-12 전남대학교산학협력단 비만 또는 제 2형 당뇨의 예방 또는 치료용 조성물
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
KR102492792B1 (ko) 2011-10-11 2023-01-30 제넨테크, 인크. 이중특이적 항체의 개선된 어셈블리
CN104094119A (zh) 2011-10-21 2014-10-08 斯特姆詹尼克斯公司 用于胞内传递生物活性分子的官能化纳米粒子
WO2013063702A1 (en) 2011-11-04 2013-05-10 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
CA2854806A1 (en) 2011-11-07 2013-05-16 Medimmune, Llc Multispecific and multivalent binding proteins and uses thereof
EP2794653B1 (en) 2011-12-23 2019-03-13 Pfizer Inc Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
TWI450727B (zh) 2011-12-29 2014-09-01 Ind Tech Res Inst 抗人類輸鐵蛋白受體的單域抗體與其應用
CN102517287B (zh) 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
KR20130114951A (ko) 2012-04-10 2013-10-21 한양대학교 산학협력단 폴리감마글루탐산을 포함하는 Th17 매개성 질환 예방 또는 치료용 조성물
JP6307080B2 (ja) 2012-09-07 2018-04-04 インセルム(インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル) 骨髄細胞に発現する誘発性受容体1(trem−1)trem様転写産物1(tlt−1)に由来する阻害ペプチドおよびその使用
KR101947702B1 (ko) * 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
CA2887825A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Engineered igg fc domains
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
US9066928B1 (en) * 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
HRP20240107T1 (hr) 2013-05-20 2024-04-12 F. Hoffmann - La Roche Ag Protutijela na transferinski receptor i postupci uporabe
KR20150010326A (ko) 2013-07-19 2015-01-28 전남대학교산학협력단 비만 및 제 2형 당뇨 또는 지방간의 예방 또는 치료용 바이아릴아마이드를 포함한 유도체 화합물
KR101402921B1 (ko) 2013-08-28 2014-06-02 전남대학교산학협력단 비만 또는 제 2형 당뇨의 치료를 위한 레스베라톨 유도체의 이용
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
CN103555829B (zh) 2013-10-12 2015-10-21 厦门人瑞生物医药科技有限公司 一种检测trem2基因r47h突变的探针、试剂盒和方法
CA2936056A1 (en) 2014-01-06 2015-07-09 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN103866041A (zh) 2014-04-04 2014-06-18 厦门大学 帕金森病和脑白质疏松症的突变检测试剂盒及其检测方法
CN106459205B (zh) 2014-04-11 2021-04-09 免疫医疗有限责任公司 包含半胱氨酸工程化抗体的轭合化合物
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
WO2016004389A2 (en) 2014-07-03 2016-01-07 Abbvie Inc. Monovalent binding proteins
SI3172232T1 (sl) 2014-07-17 2024-05-31 Novo Nordisk A/S Na mesto usmerjena mutageneza protiteles TREM-1 za zmanjšanje viskoznosti
CA2955086A1 (en) 2014-08-08 2016-02-11 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR101756417B1 (ko) 2014-08-21 2017-07-10 한국유나이티드제약 주식회사 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물
KR102506663B1 (ko) 2014-09-28 2023-03-08 더 리전트 오브 더 유니버시티 오브 캘리포니아 자극성 및 비자극성 골수성 세포의 조절
US20170334977A1 (en) 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
EP3875477A1 (en) 2015-04-17 2021-09-08 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
JP2018516901A (ja) 2015-05-18 2018-06-28 シナプテック・ディヴェロップメント・エルエルシーSynaptec Development Llc アミロイドβのガランタミンクリアランス
HK1252675A1 (zh) 2015-06-12 2019-05-31 Alector Llc 抗cd33抗体及其使用方法
JP7376977B2 (ja) 2015-06-12 2023-11-09 アレクトル エルエルシー 抗cd33抗体及びその使用方法
WO2017007712A1 (en) 2015-07-04 2017-01-12 Emory University Use of trem-1 inhibitors for treatment, elimination and eradication of hiv-1 infection
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
SMT202100527T1 (it) * 2015-07-30 2021-11-12 Macrogenics Inc Molecole di legame a pd-1 e lag-3 e loro metodi d'uso
CN108137702B (zh) 2015-08-28 2023-01-06 艾利妥 抗siglec-7抗体及其使用方法
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
WO2017062672A2 (en) 2015-10-06 2017-04-13 Alector Llc Anti-trem2 antibodies and methods of use thereof
CA3003458A1 (en) 2015-10-29 2017-05-04 Alector Llc Anti-siglec-9 antibodies and methods of use thereof
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
US12156890B2 (en) 2016-02-11 2024-12-03 The Johns Hopkins University Compositions and methods for neuralgenesis
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
US11078247B2 (en) 2016-05-04 2021-08-03 Curevac Ag RNA encoding a therapeutic protein
EP3463575B1 (en) 2016-06-01 2025-03-26 The University of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
AU2017300040A1 (en) 2016-07-22 2019-01-24 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) TREM2 cleavage modulators and uses thereof
CN106244682B (zh) 2016-07-29 2019-11-26 中山大学 Trem-2基因在鉴别猪对蓝耳病毒易感性中的应用
CN106636330B (zh) 2016-09-21 2017-12-15 郁金泰 阿尔茨海默病的诊断和治疗药物
CN110621774A (zh) 2016-10-14 2019-12-27 儿童医疗中心有限公司 用于治疗中枢神经系统疾病和病症的组合物和方法
AU2017371070B2 (en) 2016-12-09 2025-01-02 Alector Llc Anti-SIRP-alpha antibodies and methods of use thereof
EP3558340A4 (en) 2016-12-23 2020-07-22 Genervon Biopharmaceuticals LLC METHOD FOR USE OF GM6 IN DIAGNOSIS AND TREATMENT OF MORBUS ALZHEIMER
WO2018132728A1 (en) 2017-01-12 2018-07-19 Duke University Compositions and methods for the treatment of demyelinating conditions
US20190367623A1 (en) 2017-01-17 2019-12-05 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
EP3570857A1 (en) 2017-01-18 2019-11-27 Evelo Biosciences, Inc. Methods of treating cancer
CA3049791A1 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
WO2018157014A1 (en) 2017-02-24 2018-08-30 Duke University Metabolic biomarkers for the identification and characterization of alzheimer's disease
EP3589293A4 (en) 2017-02-28 2020-12-16 The Regents of the University of California DIFFERENTIATION AND USE OF HUMAN MICROGLIA-TYPE CELLS FROM PLURIPOTENT STEM CELLS AND HEMATOPOIETIC PROGENITORS
AU2018239433B2 (en) 2017-03-21 2024-02-01 Indiana University Research And Technology Corporation A genetically modified mouse expressing human APOE4p and mouse Trem2 p.R47H and methods of use thereof
KR101936249B1 (ko) 2017-04-04 2019-01-08 경희대학교 산학협력단 쿠마타케닌을 포함하는 암의 예방, 개선 또는 치료용 조성물
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20180318379A1 (en) 2017-05-01 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
WO2018213316A1 (en) 2017-05-16 2018-11-22 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
US20180340945A1 (en) 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
JP7710827B2 (ja) 2017-06-05 2025-07-22 ヤンセン バイオテツク,インコーポレーテツド 非対称なch2-ch3領域の変異を有する、操作された多重特異性抗体及び他の多量体タンパク質
US11649286B2 (en) 2017-06-25 2023-05-16 Systimmune Inc. Tri-specific antibodies
CN109206503A (zh) 2017-07-07 2019-01-15 厦门大学 一种蛋白用于制备防治阿尔茨海默病药物的用途
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
AU2018307877A1 (en) 2017-07-27 2020-01-02 Novartis Ag Sheddase resistant TREM2 variants
PE20200486A1 (es) 2017-08-03 2020-03-03 Alector Llc Anticuerpos anti-cd33 y metodos para utilizarlos
CA3061755A1 (en) 2017-08-03 2019-02-07 Alector Llc Anti-trem2 antibodies and methods of use thereof
EP3664845A4 (en) 2017-08-08 2021-03-10 Pionyr Immunotherapeutics, Inc. COMPOSITIONS AND METHODS FOR DEACTIVATING MEYLOID CELLS EXPRESSING TREM1
CA3075285A1 (en) 2017-09-14 2019-03-21 Denali Therapeutics Inc. Anti-trem2 antibodies and methods of use thereof
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
WO2019068072A1 (en) 2017-09-29 2019-04-04 The General Hospital Corporation METHODS OF IDENTIFICATION AND TREATMENT OF ADRENOMYELONEUROPATHY (AMN)
JP7361037B2 (ja) 2017-10-03 2023-10-13 プリベイル セラピューティクス,インコーポレーテッド ライソゾーム病の遺伝子治療
US20210186917A1 (en) 2017-10-17 2021-06-24 The Translational Genomics Research Institute Trem2 agonists for the stimulation of microglia and methods of identification
US10597462B1 (en) 2017-11-08 2020-03-24 University Of Puerto Rico Anti-TLT-1 antibody and uses thereof
EP3710015B1 (en) 2017-11-15 2024-01-17 Université Laval Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
CN109837330A (zh) 2017-11-28 2019-06-04 上海中优精准医疗科技股份有限公司 一种检测trem2基因多态性的探针及方法
MX2020006213A (es) 2017-12-12 2020-09-14 Pionyr Immunotherapeutics Inc Anticuerpos anti-trem2 y metodos relacionados.
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
CN111971301B (zh) 2018-01-31 2025-01-07 艾莱克特有限责任公司 抗ms4a4a抗体及其使用方法
JP2021513969A (ja) 2018-02-14 2021-06-03 イェール ユニバーシティーYale University Tremまたはtremlタンパク質を調節するための組成物および使用方法
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
WO2019180224A1 (en) 2018-03-22 2019-09-26 Nsc Therapeutics Gmbh Compounds and methods for use in the treatment of microglia-mediated disorders
EA202092302A1 (ru) 2018-04-02 2021-02-02 Бристол-Майерс Сквибб Компани Антитела к trem-1 и их применения
CA3096545A1 (en) 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
TW202448946A (zh) 2018-05-25 2024-12-16 美商阿列克特有限責任公司 抗-sirpa 抗體及其使用方法
AU2019282778A1 (en) 2018-06-08 2020-12-10 Alector Llc Anti-Siglec-7 antibodies and methods of use thereof
CN108752482B (zh) 2018-06-12 2019-04-30 南京卡提医学科技有限公司 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用
US20210195879A1 (en) 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
KR20210025614A (ko) 2018-06-29 2021-03-09 알렉터 엘엘씨 항-sirp-베타1 항체 및 그의 사용 방법
EP3820520A4 (en) 2018-07-12 2022-05-11 Corvus Pharmaceuticals, Inc. METHODS FOR DETECTING AND TREATING CANCERS HAVING ACTIVATION OF THE ADENOSINE PATHWAY
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
US12352767B2 (en) 2018-07-16 2025-07-08 University Of Virginia Patent Foundation Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity
AU2019310597A1 (en) 2018-07-27 2021-03-11 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
CN109112214A (zh) 2018-07-27 2019-01-01 复旦大学附属中山医院 模式识别受体trem2在肝癌预后和治疗中的应用
CN112912144A (zh) 2018-08-31 2021-06-04 艾利妥 抗cd33抗体及其使用方法
JP2021535181A (ja) 2018-09-05 2021-12-16 ザ ジェネラル ホスピタル コーポレイション サイトカイン放出症候群を処置する方法
CA3111569A1 (en) 2018-09-11 2020-03-19 Washington University Anti-trem-2 agonist antibodies
WO2020056114A1 (en) 2018-09-12 2020-03-19 Board Of Regents Of The University Of Nebraska Antimicrobial compositions and methods
CN113164546A (zh) 2018-09-28 2021-07-23 伊诺特伦公司 可溶的trem-1水平用于鉴定对抗炎疗法应答敏感的受试者的用途
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102096282B1 (ko) 2018-10-15 2020-04-02 재단법인대구경북과학기술원 재조합 베큘로바이러스를 이용한 인간 trem2 세포막 단백질의 효율적인 정제방법
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 trem2 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN111135185A (zh) 2018-11-02 2020-05-12 杭州星鳌生物科技有限公司 天然免疫激活通过调控髓系细胞触发受体trem2抑制大脑神经慢性炎症
EP3876956A4 (en) 2018-11-08 2022-12-28 The Regents of The University of California SYSTEMS AND METHODS FOR TARGETING CANCER CELLS
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
CA3122725A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
CN113227131B (zh) 2018-12-20 2025-03-04 豪夫迈·罗氏有限公司 经修饰的抗体Fc及其使用方法
CN109646668B (zh) 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
MA54752A (fr) 2019-01-14 2021-11-24 Univ Virginia Patent Foundation Utilisation d'inhibiteurs d'intégrine pour le traitement ou la prévention d'un trouble immunitaire neurologique et/ou d'une lésion du système nerveux
US20220104468A1 (en) 2019-01-22 2022-04-07 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
EP3914071A4 (en) 2019-01-23 2022-10-19 The Regents of the University of California Human genomic construct reporter cells and mouse models to screen therapeutics against microglia-expressed disease associated genes
CA3128350A1 (en) 2019-02-01 2020-08-06 Seattle Children's Hospital (dba Seattle Children's Research Institute) Microenvironment sensors to regulate engineered gene expression
US20220133850A1 (en) 2019-02-01 2022-05-05 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
CA3127808A1 (en) 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
PE20211979A1 (es) 2019-02-20 2021-10-05 Denali Therapeutics Inc Anticuerpos anti-trem2 y metodos para utilizarlos
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CN110320368A (zh) 2019-05-30 2019-10-11 广州医科大学附属第一医院(广州呼吸中心) 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
CN110241208A (zh) 2019-08-02 2019-09-17 辽宁中医药大学 Trem2作为早期诊断冠心病的分子标志物的应用
CN110511240B (zh) 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
CN110882262A (zh) 2019-11-06 2020-03-17 南京医科大学 一种髓细胞触发受体2的激活用药及其应用
KR102878840B1 (ko) 2019-11-22 2025-10-31 일라이 릴리 앤드 캄파니 Trem2 항체 및 그의 용도
EP3986937A1 (en) 2019-12-05 2022-04-27 Alector LLC Methods of use of anti-trem2 antibodies
CN111184742B (zh) 2020-02-13 2022-06-24 中山大学附属第五医院 Trem-2+t细胞在制备用于治疗结核病药物中的应用

Also Published As

Publication number Publication date
TWI812619B (zh) 2023-08-21
CR20190525A (es) 2020-03-20
JP2020517249A (ja) 2020-06-18
MX2019012364A (es) 2019-11-28
KR102772851B1 (ko) 2025-02-27
CO2019012998A2 (es) 2020-02-18
CL2024003661A1 (es) 2025-04-21
EP4617286A2 (en) 2025-09-17
MA52273A (fr) 2021-04-28
KR20250027855A (ko) 2025-02-27
JP7559025B2 (ja) 2024-10-01
KR20200018778A (ko) 2020-02-20
AU2022221560B2 (en) 2025-09-18
CR20210171A (es) 2021-05-21
US11186636B2 (en) 2021-11-30
BR112019021991A2 (pt) 2020-06-16
ES3035028T3 (en) 2025-08-28
JOP20190248A1 (ar) 2019-10-20
EP3612218B1 (en) 2025-04-09
AU2022221560A1 (en) 2022-09-22
MX2024000156A (es) 2024-01-23
PH12019502356A1 (en) 2020-12-07
CA3060409A1 (en) 2018-10-25
AU2018254600A1 (en) 2019-10-24
PE20250782A1 (es) 2025-03-14
AU2018254600B2 (en) 2022-05-26
US20220204611A1 (en) 2022-06-30
TW201906628A (zh) 2019-02-16
WO2018195506A1 (en) 2018-10-25
CN110709100A (zh) 2020-01-17
CL2019003000A1 (es) 2020-02-14
SG11201909646TA (en) 2019-11-28
JP2022188272A (ja) 2022-12-20
PE20200485A1 (es) 2020-03-03
EP3612218A1 (en) 2020-02-26
EP3612218A4 (en) 2021-07-28
JP7252134B2 (ja) 2023-04-04
TW202423975A (zh) 2024-06-16
US20210054069A1 (en) 2021-02-25

Similar Documents

Publication Publication Date Title
UY37698A (es) Proteínas de unión a antígenos trem2 y usos de estas
CL2021000909A1 (es) Anticuerpos estabilizadores de trem2
PH12018501882A1 (en) Binding proteins and methods of use thereof
MX2016006709A (es) Moduladores de aplnr y usos de estos.
MX2022014867A (es) Anticuerpos especificos del receptor de poliovirus humano (rvp).
UY36942A (es) Proteínas de unión a antígeno que activan el receptor de leptina
BR112019024654A2 (pt) proteína de ligação nkg2d, cd16 e ror1 ou ror2
CR20230170A (es) ANTICUERPOS ANTI-TREM2 Y MÉTODOS PARA UTILIZARLOS (divisional 2019-0485)
CL2017000278A1 (es) Moléculas biespecíficas de unión a antígeno activadoras de células t
CL2021000089A1 (es) Anticuerpos anti -sortilina y métodos para su uso.
EA201792221A1 (ru) Антитела против сортилина и способы их применения
EA201890285A1 (ru) Антитела против pd-1, активируемые антитела против pd-1 и способы их применения
PE20200486A1 (es) Anticuerpos anti-cd33 y metodos para utilizarlos
MX2017002230A (es) Anticuerpos anti-lag3 y fragmentos de union a antigeno.
UA118029C2 (uk) Модифіковане антитіло, що зв'язується з людським fcrn, й способи його застосування
MX387324B (es) Variantes de regiones fc de igg1 de humano y usos de las mismas.
MX2017006323A (es) Anticuerpos que comprenden regiones constantes pesadas modificadas.
CO2018012497A2 (es) Anticuerpos de interferón beta y usos de los mismos
MX2019010941A (es) Receptores de antigeno y usos de los mismos.
AR111914A1 (es) Proteínas de unión a antígenos trem2 y usos de estas
AR133072A2 (es) Anticuerpos aislados o fragmentos aislados de unión a antígeno de los mismos que se unen al receptor de leptina humana (lepr) y activan la señalización lepr
EA201992512A1 (ru) Антигенсвязывающие белки, связывающие trem2, и пути их применения
AR115992A2 (es) Proteínas de unión a antígeno que activan el receptor de leptina
AR122237A1 (es) Anticuerpos anti-sortilina y métodos para su uso
EA202090580A2 (ru) Триспецифичные связывающие молекулы и способы их применения

Legal Events

Date Code Title Description
110 Patent granted

Effective date: 20241030